Overview: NAD+ is essential biology, but raising a biomarker is not proof of anti-ageing benefit. Compare IV NAD+, NR and NMN evidence with current Australian TGA status.
On this page
NAD+ is essential to cellular metabolism, but that does not make every “NAD-boosting” product an established anti-ageing treatment. Human studies show that some precursors can raise blood or cellular NAD-related metabolites. The harder question—whether that produces meaningful, durable improvements in health, cognition, energy or lifespan—remains unsettled.
Australia status checked 30 September 2026: the TGA says NAD, NAD+ and NADH are not permitted ingredients in listed medicines. NMN can be used in listed medicines only under specific conditions. A product name, clinic claim or changing biomarker is not evidence that a particular product or infusion is TGA-approved.
Evidence boundary: this profile explains biochemistry, human trials and Australian regulation. It does not provide dosing, infusion, purchasing or personal treatment advice.
NAD+ at a glance
| Question | Evidence-based answer |
|---|---|
| Is NAD+ a peptide? | No. Nicotinamide adenine dinucleotide is a coenzyme found in cells. It is chemically and biologically different from a peptide. |
| Does NAD+ matter? | Yes. NAD+/NADH participates in redox reactions, energy metabolism and enzyme systems including sirtuins, PARPs and CD38. |
| Do NR and NMN raise NAD-related biomarkers? | Often, yes. Human trials commonly show biochemical target engagement, especially in blood. That does not automatically prove a clinical benefit. |
| Do NAD boosters reverse ageing? | No human trial has established that NR, NMN or IV NAD+ reverses ageing or extends human lifespan. |
| Is IV NAD+ proven for energy or wellness? | No. A 2026 systematic review found no eligible outcomes trials of IV or intramuscular NAD+ itself for anti-ageing or wellness indications. |
| What is the Australian position? | Medicine status is product-specific. The TGA says NAD, NAD+ and NADH are not permitted ingredients in listed medicines; NMN is permitted only under defined conditions. |
NAD+, NADH, NR, NMN and nicotinamide are not interchangeable
Online discussion often collapses several different molecules into one “NAD therapy” category. Their relationship is real, but their evidence cannot be transferred automatically.
| Term | What it is | What a study result can establish |
|---|---|---|
| NAD+ | The oxidised form of nicotinamide adenine dinucleotide and a cellular cofactor | Depends on the route, matrix, assay and endpoint; a blood change does not prove intact delivery to every tissue |
| NADH | The reduced electron-carrying form | A NAD+/NADH ratio is not the same measurement as total NAD |
| NR | Nicotinamide riboside, a vitamin B3-related NAD precursor | Oral NR can raise NAD-related metabolites; outcome effects vary by population and endpoint |
| NMN | Nicotinamide mononucleotide, another NAD precursor | Small human trials show target engagement and some population-specific signals; broad anti-ageing claims remain unproven |
| Nicotinamide | A vitamin B3 form used in established nutritional and clinical contexts | Evidence for a defined indication cannot be reassigned to every NAD-labelled product |
The evidence ladder: where confidence changes
1. Core biology
Established. NAD chemistry is fundamental to metabolism, redox balance and multiple enzyme systems.
2. Biomarker movement
Often demonstrated. NR and NMN commonly alter circulating or cellular NAD-related metabolites in short human studies.
3. Clinical outcomes
Mixed and context-specific. A few trials report narrow signals, while many endpoints are null or inconsistent.
4. Anti-ageing or lifespan
Not established in humans. Biomarker movement is not proof of reversed ageing, disease prevention or longer life.
What the 2026 human-evidence review found
A 2026 systematic review examined 113 intervention studies, including 33 human studies—28 randomised and five nonrandomised. Oral NR and NMN consistently showed biochemical target engagement and were generally well tolerated over weeks to months. Functional, metabolic, vascular and other healthspan outcomes were heterogeneous, often null or specific to one endpoint or population.
The review found no eligible outcomes trials of intravenous or intramuscular NAD+ itself for anti-ageing or wellness indications. One intravenous NAD+ pilot described pharmacokinetics and metabolites, not whether an infusion improved energy, cognition, function, disease or lifespan.
The central interpretation: “the intervention changed NAD biology” and “the intervention made people healthier” are different claims requiring different evidence.
Human study map: signal, result and limit
| Human evidence | Observed result | What it does not establish |
|---|---|---|
| NR in healthy middle-aged and older adults | Raised circulating NAD-related metabolites and was generally tolerated in a short crossover trial | Reversal of ageing, prevention of disease or longer lifespan |
| NMN in postmenopausal women with prediabetes | A small 10-week randomised trial found improved muscle insulin sensitivity and signalling in a specific population | A universal metabolic benefit, an effect in healthy adults or a long-term clinical outcome |
| NR in mild cognitive impairment | Raised blood NAD+ in a placebo-controlled study | That a blood increase necessarily improves cognition or brain NAD+ |
| NR in long-COVID | Raised NAD+ approximately 2.6- to 3.1-fold during treatment | The trial found no significant between-group improvement in cognition, fatigue, sleep or mood |
| Six-hour IV NAD+ pilot | Characterised changes in plasma and urinary NAD metabolites during infusion | Clinical efficacy for anti-ageing, energy, cognition, addiction treatment or wellness |
A useful case study: a biomarker rose, but outcomes did not
The 2025 long-COVID trial is a clear demonstration of why surrogate outcomes need care. NR produced a large increase in measured NAD+ during the treatment period. Yet the randomised comparison found no significant group differences in cognition, fatigue, sleep quality, anxiety or depression. Exploratory within-group findings can help design future research, but they do not replace the prespecified placebo comparison.
For a practical guide to endpoints, dropouts and exploratory analyses, use our clinical-trial interpretation framework.
Why blood NAD+ is not a whole-body verdict
NAD biology is compartmentalised. Whole blood, plasma, peripheral blood mononuclear cells, skeletal muscle and brain are different matrices. Sample handling, oxidation control, timing and analytical method can also alter what is measured. A result in one compartment cannot simply be assigned to every organ.
- Identity: which molecule and metabolite panel did the assay measure?
- Matrix: whole blood, plasma, cells or tissue?
- Timing: fasting, post-dose, during infusion or after clearance?
- Outcome: biochemical target engagement or a patient-important result?
- Validation: was the method fit for that matrix and research question?
Read our mass spectrometry and HPLC evidence guide for the broader distinction between identifying a chemical signal and establishing a clinical claim.
IV NAD+ evidence: what the pilot can and cannot show
The frequently cited Australian six-hour infusion study was a small pharmacokinetic and metabolomic pilot. It measured how NAD-related compounds changed in plasma and urine during and after infusion. That is useful mechanism work. It was not a randomised outcomes trial and cannot establish anti-ageing, cognitive, energy, recovery or addiction-treatment efficacy.
Route alone does not settle tissue delivery. Molecules in the circulation can be metabolised or cleaved before their components enter cells. A claim that an infusion is “100% bioavailable” therefore does not answer whether intact NAD+ reached the relevant intracellular compartment or changed a meaningful health outcome.
NAD and NMN in Australia: current TGA position
The TGA updated its consumer and sponsor information on 3 February 2026 and issued detailed advertising guidance on 12 August 2026. The key distinctions are:
| Australian question | Current answer |
|---|---|
| Are NAD, NAD+ and NADH permitted ingredients in listed medicines? | No. The TGA says they are currently not permitted ingredients in listed medicines. |
| Can NMN appear in a listed medicine? | Yes, but only when all current ingredient, sponsor, route, indication and other TGA conditions are satisfied. |
| Does “AUST L” prove an anti-ageing benefit? | No. Listed medicines use low-level indications from a permitted framework; an AUST number is not proof of a broad longevity claim. |
| What if there is no AUST number? | The TGA warns that products making therapeutic claims may be unapproved or unlawfully supplied unless an exemption or other authorisation applies. |
| Does a clinic service make a product TGA-approved? | No. Product inclusion, professional practice and the evidence for a claimed outcome are separate questions. |
Use the TGA’s own register for a product-level check and read our Australia and TGA regulation guide before interpreting “approved”, “listed”, “compounded” or “practitioner supplied” as interchangeable terms.
How to read an NAD claim in 60 seconds
- Name the intervention: NAD+, NADH, NR, NMN or nicotinamide.
- Name the route: oral evidence cannot automatically validate an infusion, and vice versa.
- Find the population: healthy adults, prediabetes, cognitive impairment and long-COVID are not interchangeable.
- Separate biomarker from benefit: rising NAD metabolites may show target engagement without improving how a participant feels or functions.
- Check the comparator and duration: uncontrolled short studies cannot answer long-term anti-ageing questions.
- Check Australian status: find the exact AUST entry or other lawful pathway, not a category-level marketing statement.
Frequently asked questions
Is NAD+ a peptide?
No. NAD+ is a dinucleotide coenzyme. It is included in this library because it is frequently marketed alongside peptides and longevity interventions, not because it is chemically a peptide.
Does NAD+ decline with age?
Age-related changes have been reported, but the strength and direction depend on tissue, matrix, assay and population. Human evidence is less uniform than broad marketing claims suggest.
Do NAD+ infusions reverse ageing?
No human outcomes trial has established that IV NAD+ reverses ageing or extends lifespan. Existing infusion work is largely pharmacokinetic, biomarker or tolerability research.
Are NR and NMN the same as NAD+?
No. They are precursors used by biosynthetic pathways. Evidence that one precursor changes a biomarker does not prove that direct NAD+, another precursor or another route will produce the same result.
Does a higher blood NAD+ result mean better health?
Not necessarily. It may demonstrate biochemical target engagement. Clinical benefit requires separate evidence using meaningful, prespecified outcomes.
Are NAD or NMN products approved in Australia?
Status is product-specific. The TGA says NAD, NAD+ and NADH are not permitted ingredients in listed medicines. NMN can be used in listed medicines only under specific current conditions. Check the exact ARTG entry rather than relying on a product name or clinic claim.
Primary and official sources
- TGA: NAD, NAD+, NADH or NMN medicines sold in Australia, updated 3 February 2026.
- TGA: representations for NAD- and NMN-related listed medicines, 12 August 2026.
- Gallagher and Emmanuel: systematic review of NAD+ supplementation for anti-ageing and wellness, 2026.
- Grant et al.: human plasma and urine NAD+ metabolome during a six-hour infusion, 2019.
- Yoshino et al.: NMN and muscle insulin sensitivity in women with prediabetes, 2021.
- NR placebo-controlled trial in older adults with mild cognitive impairment, 2023.
- Wu et al.: NR, cognition and symptom recovery in long-COVID, 2025.
- Martens et al.: NR tolerability and NAD+ metabolites in healthy older adults, 2018.
- ClinicalTrials.gov: NAD-brain pharmacokinetic study.
Reviewed 30 September 2026. Educational information only; no dosing, infusion, purchasing or personal medical advice.
How to cite this research profile
NAD+ Australia: Human Evidence, IV Infusions, NR, NMN and TGA Status. Elite Peps Australia. Published 30 June 2026; updated 30 September 2026. https://elitepepsaustralia.com/product/nad-plus/
Verification: Follow the linked primary studies, trial records and regulator documents in the references above. Regulatory status is date-sensitive.